cHCC-CCA harbored recurrent alterations in TERT (80%), TP53 (80%), cell cycle genes (40%; CCND1, CCNE1, CDKN2A), RTK/Ras/PI3K/AKT signaling pathway genes (55%; ERBB2, KRAS, MET, PTEN), chromatin regulators (20%; ARID1A, ARID2), and Wnt pathway genes (20%; APC, AXIN, CTNNB1). The gene discussed is KRAS; the disease is cholangiocarcinoma.